Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

By K. Choopanya, Michael Martin, P. Suntharasamai, Udomsak Sangkum, P. Mock, M. Leethochawalit, Sithisat Chiamwongpaet, Praphan Kitisin, Pitinan Natrujirote, Somyot Kittimunkong and 7 more. The Lancet, 2013

1,352 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/f6260c8ae9f53e794d311cc3aeb545a4e3f5769d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. V. Fonner
2. Sarah L Dalglish
3. C. Kennedy
4. K. O'reilly
5. R. Baggaley
6. Florence M. Koechlin
7. J. Molina
8. M. Rodolph

Citations in the corpus

• Effectiveness and safety of oral HIV preexposure prophylaxis for all populations (2016, background): “Drug resistance Six trials measured and reported cases of TDF or FTC drug resistance, identified using standardized clinical genotypic laboratory assays [8,18,24,32,45,47].”
• On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. (2015, background): “Any serious adverse event 20 (10) 17 (8) 0.”
• Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women (2015, neutral): “(%)‡ 163 (3) 42 (4) 27 (3) 34 (3) 24 (2) 36 (4)”